A multifaceted study of human papillomavirus and prostate carcinoma

Howard Strickler, Robert D. Burk, Keerti Shah, Raphael Viscidi, Aaron Jackson, Giancarlo Pizza, Franco Bertoni, John T. Schiller, Angela Manns, Robert Metcalf, Weimin Qu, James J. Goedert

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

BACKGROUND. The presence of human papillomavirus (HPV) in the prostate and its role in prostate carcinoma are in dispute. To address these issues, two laboratories with extensive HPV experience were selected to test specimens from two populations at different risk for prostate carcinoma, using three different polymerase chain reaction (PCR) assays and two serologic assays for HPV. METHODS. The cases were comprised of 51 African- American (men at high risk for prostate carcinoma) and 15 Italian (men at intermediate risk for prostate carcinoma) men with prostate carcinoma. Controls were 108 African-American men and 40 Italian men with histologically proven benign prostate hypertrophy (BPH). Prostate tissue was obtained from each patient at surgery and immediately frozen in liquid nitrogen. The PCR primer sets included two (MY09/MY11 and GP5+/ GP6+) that amplify different regions of L1 and a third (WD66,67,154/WD72,76) targeted to E6. Sensitivity in the 2 L1 PCR assays was shown to be 1 HPV DNA genome per 100 cells. Serum antibodies to HPV-16 and HPV-11 virus-like particles (VLPs) were detected using enzyme-linked immunosorbent assays. RESULTS. All available prostate carcinoma tissue specimens (n = 63) and BPH specimens from selected controls (n = 61) were tested by PCR. Human β-globin DNA could be amplified from all specimens except three carcinomas, but no HPV DNA was detected in any case or control specimens by MY09/MY11 or E6 PCR. Microdissection of 27 carcinoma specimens was conducted to minimize nontumor DNA, but results remained negative by MY09/MY11 and GP5+/GP6+ PCR. In addition, serum specimens in cases (n = 63) and controls (n = 144) showed no differences in their responses against HPV-16 (P = 0.54) or HPV-11 VLPs (P = 0.64). CONCLUSIONS. The findings suggest that HPV is not associated with prostate carcinoma, and that HPV DNA is not at all common in the prostate glands of older men.

Original languageEnglish (US)
Pages (from-to)1118-1125
Number of pages8
JournalCancer
Volume82
Issue number6
DOIs
StatePublished - Mar 15 1998

Fingerprint

Prostate
Carcinoma
Papillomaviridae
Polymerase Chain Reaction
DNA
Human papillomavirus 11
Human papillomavirus 16
African Americans
Virion
Hypertrophy
Microdissection
Dissent and Disputes
Globins
Serum
Nitrogen
Enzyme-Linked Immunosorbent Assay
Genome
Antibodies

Keywords

  • Benign prostate hypertrophy
  • Human papillomavirus
  • Polymerase chain reaction
  • Prostate carcinoma
  • Serology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A multifaceted study of human papillomavirus and prostate carcinoma. / Strickler, Howard; Burk, Robert D.; Shah, Keerti; Viscidi, Raphael; Jackson, Aaron; Pizza, Giancarlo; Bertoni, Franco; Schiller, John T.; Manns, Angela; Metcalf, Robert; Qu, Weimin; Goedert, James J.

In: Cancer, Vol. 82, No. 6, 15.03.1998, p. 1118-1125.

Research output: Contribution to journalArticle

Strickler, H, Burk, RD, Shah, K, Viscidi, R, Jackson, A, Pizza, G, Bertoni, F, Schiller, JT, Manns, A, Metcalf, R, Qu, W & Goedert, JJ 1998, 'A multifaceted study of human papillomavirus and prostate carcinoma', Cancer, vol. 82, no. 6, pp. 1118-1125. https://doi.org/10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9
Strickler, Howard ; Burk, Robert D. ; Shah, Keerti ; Viscidi, Raphael ; Jackson, Aaron ; Pizza, Giancarlo ; Bertoni, Franco ; Schiller, John T. ; Manns, Angela ; Metcalf, Robert ; Qu, Weimin ; Goedert, James J. / A multifaceted study of human papillomavirus and prostate carcinoma. In: Cancer. 1998 ; Vol. 82, No. 6. pp. 1118-1125.
@article{8d7ef99bdb454380807e1efc36b1acf6,
title = "A multifaceted study of human papillomavirus and prostate carcinoma",
abstract = "BACKGROUND. The presence of human papillomavirus (HPV) in the prostate and its role in prostate carcinoma are in dispute. To address these issues, two laboratories with extensive HPV experience were selected to test specimens from two populations at different risk for prostate carcinoma, using three different polymerase chain reaction (PCR) assays and two serologic assays for HPV. METHODS. The cases were comprised of 51 African- American (men at high risk for prostate carcinoma) and 15 Italian (men at intermediate risk for prostate carcinoma) men with prostate carcinoma. Controls were 108 African-American men and 40 Italian men with histologically proven benign prostate hypertrophy (BPH). Prostate tissue was obtained from each patient at surgery and immediately frozen in liquid nitrogen. The PCR primer sets included two (MY09/MY11 and GP5+/ GP6+) that amplify different regions of L1 and a third (WD66,67,154/WD72,76) targeted to E6. Sensitivity in the 2 L1 PCR assays was shown to be 1 HPV DNA genome per 100 cells. Serum antibodies to HPV-16 and HPV-11 virus-like particles (VLPs) were detected using enzyme-linked immunosorbent assays. RESULTS. All available prostate carcinoma tissue specimens (n = 63) and BPH specimens from selected controls (n = 61) were tested by PCR. Human β-globin DNA could be amplified from all specimens except three carcinomas, but no HPV DNA was detected in any case or control specimens by MY09/MY11 or E6 PCR. Microdissection of 27 carcinoma specimens was conducted to minimize nontumor DNA, but results remained negative by MY09/MY11 and GP5+/GP6+ PCR. In addition, serum specimens in cases (n = 63) and controls (n = 144) showed no differences in their responses against HPV-16 (P = 0.54) or HPV-11 VLPs (P = 0.64). CONCLUSIONS. The findings suggest that HPV is not associated with prostate carcinoma, and that HPV DNA is not at all common in the prostate glands of older men.",
keywords = "Benign prostate hypertrophy, Human papillomavirus, Polymerase chain reaction, Prostate carcinoma, Serology",
author = "Howard Strickler and Burk, {Robert D.} and Keerti Shah and Raphael Viscidi and Aaron Jackson and Giancarlo Pizza and Franco Bertoni and Schiller, {John T.} and Angela Manns and Robert Metcalf and Weimin Qu and Goedert, {James J.}",
year = "1998",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9",
language = "English (US)",
volume = "82",
pages = "1118--1125",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - A multifaceted study of human papillomavirus and prostate carcinoma

AU - Strickler, Howard

AU - Burk, Robert D.

AU - Shah, Keerti

AU - Viscidi, Raphael

AU - Jackson, Aaron

AU - Pizza, Giancarlo

AU - Bertoni, Franco

AU - Schiller, John T.

AU - Manns, Angela

AU - Metcalf, Robert

AU - Qu, Weimin

AU - Goedert, James J.

PY - 1998/3/15

Y1 - 1998/3/15

N2 - BACKGROUND. The presence of human papillomavirus (HPV) in the prostate and its role in prostate carcinoma are in dispute. To address these issues, two laboratories with extensive HPV experience were selected to test specimens from two populations at different risk for prostate carcinoma, using three different polymerase chain reaction (PCR) assays and two serologic assays for HPV. METHODS. The cases were comprised of 51 African- American (men at high risk for prostate carcinoma) and 15 Italian (men at intermediate risk for prostate carcinoma) men with prostate carcinoma. Controls were 108 African-American men and 40 Italian men with histologically proven benign prostate hypertrophy (BPH). Prostate tissue was obtained from each patient at surgery and immediately frozen in liquid nitrogen. The PCR primer sets included two (MY09/MY11 and GP5+/ GP6+) that amplify different regions of L1 and a third (WD66,67,154/WD72,76) targeted to E6. Sensitivity in the 2 L1 PCR assays was shown to be 1 HPV DNA genome per 100 cells. Serum antibodies to HPV-16 and HPV-11 virus-like particles (VLPs) were detected using enzyme-linked immunosorbent assays. RESULTS. All available prostate carcinoma tissue specimens (n = 63) and BPH specimens from selected controls (n = 61) were tested by PCR. Human β-globin DNA could be amplified from all specimens except three carcinomas, but no HPV DNA was detected in any case or control specimens by MY09/MY11 or E6 PCR. Microdissection of 27 carcinoma specimens was conducted to minimize nontumor DNA, but results remained negative by MY09/MY11 and GP5+/GP6+ PCR. In addition, serum specimens in cases (n = 63) and controls (n = 144) showed no differences in their responses against HPV-16 (P = 0.54) or HPV-11 VLPs (P = 0.64). CONCLUSIONS. The findings suggest that HPV is not associated with prostate carcinoma, and that HPV DNA is not at all common in the prostate glands of older men.

AB - BACKGROUND. The presence of human papillomavirus (HPV) in the prostate and its role in prostate carcinoma are in dispute. To address these issues, two laboratories with extensive HPV experience were selected to test specimens from two populations at different risk for prostate carcinoma, using three different polymerase chain reaction (PCR) assays and two serologic assays for HPV. METHODS. The cases were comprised of 51 African- American (men at high risk for prostate carcinoma) and 15 Italian (men at intermediate risk for prostate carcinoma) men with prostate carcinoma. Controls were 108 African-American men and 40 Italian men with histologically proven benign prostate hypertrophy (BPH). Prostate tissue was obtained from each patient at surgery and immediately frozen in liquid nitrogen. The PCR primer sets included two (MY09/MY11 and GP5+/ GP6+) that amplify different regions of L1 and a third (WD66,67,154/WD72,76) targeted to E6. Sensitivity in the 2 L1 PCR assays was shown to be 1 HPV DNA genome per 100 cells. Serum antibodies to HPV-16 and HPV-11 virus-like particles (VLPs) were detected using enzyme-linked immunosorbent assays. RESULTS. All available prostate carcinoma tissue specimens (n = 63) and BPH specimens from selected controls (n = 61) were tested by PCR. Human β-globin DNA could be amplified from all specimens except three carcinomas, but no HPV DNA was detected in any case or control specimens by MY09/MY11 or E6 PCR. Microdissection of 27 carcinoma specimens was conducted to minimize nontumor DNA, but results remained negative by MY09/MY11 and GP5+/GP6+ PCR. In addition, serum specimens in cases (n = 63) and controls (n = 144) showed no differences in their responses against HPV-16 (P = 0.54) or HPV-11 VLPs (P = 0.64). CONCLUSIONS. The findings suggest that HPV is not associated with prostate carcinoma, and that HPV DNA is not at all common in the prostate glands of older men.

KW - Benign prostate hypertrophy

KW - Human papillomavirus

KW - Polymerase chain reaction

KW - Prostate carcinoma

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=0032520768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032520768&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9

DO - 10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9

M3 - Article

C2 - 9506358

AN - SCOPUS:0032520768

VL - 82

SP - 1118

EP - 1125

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -